Market Cap 4.61B
Revenue (ttm) 0.00
Net Income (ttm) -109.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,817,200
Avg Vol 5,029,834
Day's Range N/A - N/A
Shares Out 113.04M
Stochastic %K 54%
Beta 0.64
Analysts Strong Sell
Price Target $89.82

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selectiv...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 704 4660
Address:
9920 Pacific Heights Boulevard, Suite 350, San Diego, United States
Torstenbraun
Torstenbraun Nov. 14 at 10:32 AM
0 · Reply
LiverPlayer
LiverPlayer Nov. 14 at 8:51 AM
$VKTX No interest if this doubles or halves in short term. This has real potential to be 10x in two years, even more later. Risks of Vanquish trials crashing and failing, IMO not likely. Never seen a risk/reward as good as this before. Company will want to partner for a MASH P3 trial - as they are complicated and will eat huge amounts of money. That wont go to P3 unless they partner. Don't see any benefit to partnering for VK2735, easy do this themselves (even through to commercialisation). Should get a bump in SP soon when they announce completion of enrollment for Vanquish 1. Buy-out? Could easily happen anytime - but BO price needs to be in region of $150 even at this stage of development. Anyone know where I can find details of the study protocol for Vanquish - wondering if they have built in any interim analysis into their study design. VK2735 will hit all endpoints way before 78weeks. GLTA - my advice, don't sell a single share no matter what price does over next 12-18months.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 14 at 8:23 AM
💎 LiquidTheta® Live Actionable Trade Asset: $VKTX Contracts: $VKTX January 15, 2027 $40 Calls Scale in: $13.77- $16.82 Scale out: $53.53-$91.77 Profit Potential : 96% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
bavariaron
bavariaron Nov. 14 at 8:16 AM
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 7:08 AM
Hedge Alert Live - Protect Your Portfolio Contract: $VKTX $39.00 Put · NOV 21, 2025 Exp Entry Price: $2.50 - $3.60 Exit Price Target: $3.85 Profit Margin: +54% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
NoFearHere
NoFearHere Nov. 14 at 6:06 AM
$VKTX that back these topped out looking a little tired However it's started a bullish " GOLDEN CROSS" SPRTS=37.70+36.09+35+33.66+32+31.30 @50 dma
0 · Reply
Rajeshbuffet
Rajeshbuffet Nov. 14 at 5:22 AM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:44 AM
$VKTX is currently trading at $39.0, showing a strong market context with an RSI of 62.57, indicating bullish momentum but approaching overbought territory. The 30-day moving average (MA30) at 35.1 and the 50-day moving average (MA50) at 31.3 suggest a solid upward trend, as the price is well above both averages. The 60-day high of 43.15 provides a resistance level, while the low of 22.96 indicates significant support. Directional bias is bullish due to the positive relationship between the current price and the moving averages. Suggested entry is at $39.5, slightly above the last close to confirm upward momentum. Set a stop loss at $36.5 to manage risk. Targets are $42.0 (near the 60D high) and $44.0, allowing for potential gains while monitoring RSI for overbought signals. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
chuckieclam
chuckieclam Nov. 14 at 4:13 AM
$VKTX colon cancer help with GLP1 https://firstwordpharma.com/story/6528207
0 · Reply
LastResort
LastResort Nov. 14 at 3:42 AM
$VKTX still blocked.
1 · Reply
Latest News on VKTX
Viking Therapeutics: The Prime Target In The Obesity Gold Rush

Oct 23, 2025, 10:05 AM EDT - 21 days ago

Viking Therapeutics: The Prime Target In The Obesity Gold Rush


Viking Therapeutics: A Speculative Buy

Oct 4, 2025, 9:44 AM EDT - 5 weeks ago

Viking Therapeutics: A Speculative Buy


Viking Therapeutics: Overdue For Gains

Sep 28, 2025, 2:00 PM EDT - 6 weeks ago

Viking Therapeutics: Overdue For Gains


Viking: Still On Track, But The Compass Needs Recalibration

Aug 23, 2025, 6:57 AM EDT - 2 months ago

Viking: Still On Track, But The Compass Needs Recalibration


Viking Therapeutics: Panic Creates Opportunity

Aug 20, 2025, 8:52 PM EDT - 3 months ago

Viking Therapeutics: Panic Creates Opportunity


Viking Therapeutics: What's Happening With VKTX Stock?

Aug 20, 2025, 9:50 AM EDT - 3 months ago

Viking Therapeutics: What's Happening With VKTX Stock?


Viking Therapeutics: Still On Track

Aug 18, 2025, 8:56 PM EDT - 3 months ago

Viking Therapeutics: Still On Track


Viking Therapeutics Q2: Confidently Continuing The Recovery

Jul 25, 2025, 10:15 AM EDT - 3 months ago

Viking Therapeutics Q2: Confidently Continuing The Recovery


What's Going On With Viking Therapeutics Stock On Wednesday?

Jun 25, 2025, 1:01 PM EDT - 5 months ago

What's Going On With Viking Therapeutics Stock On Wednesday?


Viking Therapeutics: Buy It For The Future And Ignore The Noise

May 27, 2025, 9:00 AM EDT - 6 months ago

Viking Therapeutics: Buy It For The Future And Ignore The Noise


Viking Therapeutics: Weight-Loss Story Remains Intact

May 22, 2025, 7:24 AM EDT - 6 months ago

Viking Therapeutics: Weight-Loss Story Remains Intact


Viking Therapeutics: Near-Term Catalysts And Competitor Readouts

May 20, 2025, 6:49 AM EDT - 6 months ago

Viking Therapeutics: Near-Term Catalysts And Competitor Readouts


Torstenbraun
Torstenbraun Nov. 14 at 10:32 AM
0 · Reply
LiverPlayer
LiverPlayer Nov. 14 at 8:51 AM
$VKTX No interest if this doubles or halves in short term. This has real potential to be 10x in two years, even more later. Risks of Vanquish trials crashing and failing, IMO not likely. Never seen a risk/reward as good as this before. Company will want to partner for a MASH P3 trial - as they are complicated and will eat huge amounts of money. That wont go to P3 unless they partner. Don't see any benefit to partnering for VK2735, easy do this themselves (even through to commercialisation). Should get a bump in SP soon when they announce completion of enrollment for Vanquish 1. Buy-out? Could easily happen anytime - but BO price needs to be in region of $150 even at this stage of development. Anyone know where I can find details of the study protocol for Vanquish - wondering if they have built in any interim analysis into their study design. VK2735 will hit all endpoints way before 78weeks. GLTA - my advice, don't sell a single share no matter what price does over next 12-18months.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 14 at 8:23 AM
💎 LiquidTheta® Live Actionable Trade Asset: $VKTX Contracts: $VKTX January 15, 2027 $40 Calls Scale in: $13.77- $16.82 Scale out: $53.53-$91.77 Profit Potential : 96% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
bavariaron
bavariaron Nov. 14 at 8:16 AM
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 7:08 AM
Hedge Alert Live - Protect Your Portfolio Contract: $VKTX $39.00 Put · NOV 21, 2025 Exp Entry Price: $2.50 - $3.60 Exit Price Target: $3.85 Profit Margin: +54% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
NoFearHere
NoFearHere Nov. 14 at 6:06 AM
$VKTX that back these topped out looking a little tired However it's started a bullish " GOLDEN CROSS" SPRTS=37.70+36.09+35+33.66+32+31.30 @50 dma
0 · Reply
Rajeshbuffet
Rajeshbuffet Nov. 14 at 5:22 AM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:44 AM
$VKTX is currently trading at $39.0, showing a strong market context with an RSI of 62.57, indicating bullish momentum but approaching overbought territory. The 30-day moving average (MA30) at 35.1 and the 50-day moving average (MA50) at 31.3 suggest a solid upward trend, as the price is well above both averages. The 60-day high of 43.15 provides a resistance level, while the low of 22.96 indicates significant support. Directional bias is bullish due to the positive relationship between the current price and the moving averages. Suggested entry is at $39.5, slightly above the last close to confirm upward momentum. Set a stop loss at $36.5 to manage risk. Targets are $42.0 (near the 60D high) and $44.0, allowing for potential gains while monitoring RSI for overbought signals. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
chuckieclam
chuckieclam Nov. 14 at 4:13 AM
$VKTX colon cancer help with GLP1 https://firstwordpharma.com/story/6528207
0 · Reply
LastResort
LastResort Nov. 14 at 3:42 AM
$VKTX still blocked.
1 · Reply
saifnila2
saifnila2 Nov. 14 at 3:29 AM
$VKTX why did it take a year and a half to release the results of the metabolic study . Thats a head scratcher. They had this data for a long time. Today's action took a lot of air out of the stock and now we need to see recovery. Next week we will be able to hear from sleepy again and see if anything new.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 14 at 2:56 AM
Enter: $VKTX Calls Strike Price: $39 Expiry Date: DEC 05 2025 Buy in Price: $5.10 - $5.47 Sell Price: $8.48 Profit : +55% (Turn every $1 into $1.55) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
LastResort
LastResort Nov. 14 at 1:23 AM
$VKTX hella bullish 😂😂😂 been like this for 20 minutes
1 · Reply
killbilltrader
killbilltrader Nov. 14 at 1:13 AM
$VKTX I think BMS would be the ultimate buyer of VKTX. Could be JNJ too but I bet on BMS.
2 · Reply
Axadude
Axadude Nov. 14 at 12:58 AM
0 · Reply
LastResort
LastResort Nov. 13 at 11:23 PM
$VKTX careful, $60 could come faster than you might think.
3 · Reply
biolover
biolover Nov. 13 at 11:15 PM
$VKTX Viking DACRA is very potent in primates. Due to low API and low vomit rate for whole class, can be used therapeutic and maintenance. Issue with all amylin class is fatigue and bradycardia.
1 · Reply
Wal187
Wal187 Nov. 13 at 11:13 PM
$VKTX Gettin the impression nvo is going to come after viking aggressively https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-ceo-signals-new-appetite-risk-obesity-deals-2025-11-12/
1 · Reply
biolover
biolover Nov. 13 at 11:13 PM
$VKTX these are hyper responders. Tirzepatide got about 10-11 % at 16 wks. If we get 12-13% average will be great. Remember Vk starts at 1.5 mg while Tirzepatide 2.5 mg. But these anecdotes are encouraging. I heard from one pt no vomiting so far from one site of 60 pts on trials. This is remarkable as this is large size sample and could predict blast outcome.
0 · Reply
DG20
DG20 Nov. 13 at 11:12 PM
$VKTX Since technically DACRA is undergoing an IND it could be held up currently because they plan combine with VK2735 maintenance trial since that’s also a phase 1 trial. Would certainly give potential for a big splash @ 31wks. This is often done in oncology… Thoughts everyone???
0 · Reply
biolover
biolover Nov. 13 at 11:08 PM
$VKTX oral amylin from Viking in 2026 will be blast. I don’t consider it that critical long term. But market loves this shit.
0 · Reply
Muddymac
Muddymac Nov. 13 at 10:53 PM
$VKTX Low volume and bad market day. Ignore today.
2 · Reply